

AMENDMENT TO THE SPECIFICATION

Please replace the paragraph beginning at page 7, line 24, with the following rewritten paragraph:

The corresponding reverse control of oligonucleotide sequences are SEQ ID NO:6 and 7. These antisense oligonucleotides may revert the transformed phenotype of cancer cell lines with respect to focus formation, decrease in proliferation, and stimulation of apoptosis. Because inhibition of nucleotide exchange on Ras may revert the phenotype of RTK-transformed cell lines, Sos1 is a putative therapeutic target for Sos1 antisense or a small molecule.

Please replace the paragraph beginning at page 69, line 2, with the following rewritten paragraph:

Using the methods of Example 1, for antisense treatment, cells are treated with an oligonucleotide based on the Sos1 sequence: AACAGAAGCTGATCGCATAGC (SEQ ID NO:15). Two complementary ribonucleotide monomers with deoxy-TT extensions at the 3' end are synthesized and annealed. Cells of the BT474 cell line are treated with 50-200 nM RNAi with 1:3 L2 lipitoid. Cells are harvested on day 1, 2, 3 and 4, and analyzed for Sos1 protein by Western analysis, as is known in the art.